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Abstract
Objective: Drug users and HIV-seropositive individuals often show deficits in decision-making; however the nature of these
deficits is not well understood. Recent studies have employed computational modeling approaches to disentangle the
psychological processes involved in decision-making. Although such approaches have been used successfully with a
number of clinical groups including drug users, no study to date has used computational modeling to examine the effects
of HIV on decision-making. In this study, we use this approach to investigate the effects of HIV and drug use on decision-
making processes in women, who remain a relatively understudied population.
Method: Fifty-seven women enrolled in the Women’s Interagency HIV Study (WIHS) were classified into one of four groups
based on their HIV status and history of crack cocaine and/or heroin drug use (DU): HIV+/DU+ (n = 14); HIV+/DU2 (n = 17);
HIV2/DU+ (n = 14); and HIV2/DU2 (n = 12). We measured decision-making with the Iowa Gambling Task (IGT) and
examined behavioral performance and model parameters derived from the best-fitting computational model of the IGT.
Results: Although groups showed similar behavioral performance, HIV and DU exhibited differential relationship to model
parameters. Specifically, DU was associated with compromised learning/memory and reduced loss aversion, whereas HIV
was associated with reduced loss aversion, but was not related to other model parameters.
Conclusions: Results reveal that HIV and DU have differential associations with distinct decision-making processes in
women. This study contributes to a growing line of literature which shows that different psychological processes may
underlie similar behavioral performance in various clinical groups and may be associated with distinct functional outcomes.
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Introduction
HIV and drug addiction are truly linked epidemics [1] with
known effects on fronto-striatal systems and associated impair-
ments in executive cognitive functions [2–4]. Among the latter,
decision-making is often prominently affected in HIV-seropos-
itive (HIV+) [5,6] and HIV-seronegative (HIV2) drug users
[7–10].
‘‘Decision-making’’ is typically defined as the ability to select
advantageously from an array of available options, such that
response selections result in long-term positive outcomes. It is often
studied using laboratory tasks such as the Iowa Gambling Task
(IGT), which simulates real-life situations in the way it involves
uncertainty, reward, and punishment [11]. The IGT was
developed originally to capture deficits in decision-making among
persons with focal lesions of the ventromedial prefrontal cortex
[11,12] who displayed seeming indifference to the long-term
consequences of their actions, as evidenced by excessive choices of
immediately attractive but ultimately disadvantageous outcomes.
Substance dependent individuals typically show impaired perfor-
mance on this task [7,8,13–16]. Recently, decision-making has
received increased attention in the HIV literature [5,6,17,18], in
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e68962
large part because of its association with behaviors that increase
risk for HIV infection and transmission [19].
The IGT is a complex task and poor behavioral performance
could be the result of deficits in various distinct component
processes, such as hypersensitivity to reward and/or hyposensitiv-
ity to losses, failure to learn from past outcomes and losses, and/or
erratic and impulsive response style [20,21]. In a series of studies,
Busemeyer, Stout and their colleagues [20,22,23] have developed
mathematical models of the task that capture the complex
interplay of cognitive and motivational processes involved in
decision-making. The use of such models allows one to decompose
IGT behavioral performance into distinct cognitive, motivational,
and response processes, thereby providing a fine-grained analysis
of the underlying decision-making processes and characterizing
more precisely the decision-making deficits of different clinical
groups. Computational modeling has been used successfully to
investigate components of impaired IGT performance among
drug users [20,24,25], incarcerated criminal offenders [21],
patients with bipolar disorder [26], schizophrenia [27], autism
spectrum disorders [28], and Huntington’s disease [29]. Studies
applying this approach show that although behavioral perfor-
mance may be similar across different clinical groups, the cognitive
processes that underlie these behavioral profiles may vary across
groups in clinically meaningful ways.
To our knowledge, no studies to date have investigated the IGT
performance of HIV-seropositive individuals using the computa-
tional modeling approach, despite evidence that HIV has
detrimental effects on executive function and decision-making
which have become even more pronounced since the advent of
combination highly active antiretroviral therapy (cART) [3].
There is evidence that male HIV+ drug users perform the IGT
significantly more poorly (i.e., make significantly more disadvan-
tageous card selections) compared with demographically matched
HIV2 drug users [6]. Similarly, Hardy et al. [5] and Thames et al.
[18] revealed that a gender mixed group (34% women in [5] and
24% women in [18]) of HIV+ drug users and non-drug users made
significantly more disadvantageous choices on the IGT than
HIV2 controls. Yet, neither one of these studies reported IGT
results separately by gender nor did they control for gender in their
analyses. Overall, no studies to date have investigated the integrity
of decision-making mechanisms in HIV+ women as a function of
HIV and drug use. This is not entirely surprising, given that
women have been generally under-represented in neuropsycho-
logical studies of HIV [30]. Yet, HIV+ women may be at greater
risk for cognitive decline than HIV+ men [30–32] and there are
known gender differences in decision-making on the IGT, with
males typically outperforming females on the task [11,33,34].
In the current investigation, we tested three computational
models of the IGT in a sample of HIV+ and HIV2 women with
and without a history of crack cocaine and/or heroin use. We
evaluated both the standard behavioral performance scores from
the IGT, as well as model parameters derived from the best-fitting
computational model, in order to determine if those differ
systematically according to HIV serostatus and/or history of drug
use. We hypothesized that HIV+ women with a history of drug use
would be most impaired on the task and that the performance of
HIV2 women with no history of drug use would be impaired
least. In line with the literature [20,23–25], we hypothesized that a
history of drug use would be related to loss aversion and reward
sensitivity, with the caveat that more specific predictions were
precluded due to the relatively limited literature with women on
decision-making. For similar reasons, we did not make more
specific predictions regarding how HIV might affect specific IGT
components, although we expected that HIV+ women would
evidence impaired performance on the task. Finally, in order to
follow up on our earlier finding that performance on the IGT may
relate to risky behaviors [19] and to examine the relationships
between model parameters and functional outcomes, we evaluated
the associations between component processes of the IGT and
risky sexual practices and with how closely HIV+ participants
followed their recommended medication schedule. We hypothe-
sized that high sensitivity to reward and/or reduced sensitivity to
loss would be related to more risky behaviors and poorer
adherence to HIV medication schedules and that this effect would
be more pronounced in HIV+ women with a history of drug use.
Methods
Ethics Statement
The study was conducted according to the principles expressed
in the Declaration of Helsinki. The study protocol was approved
by the Institutional Review Boards at University of Illinois at
Chicago and the Cook County Health and Hospitals System. All
enrolled participants gave written informed consent for partici-
pating in the study.
Participants
Fifty-seven women were recruited from the Chicago site of the
Women’s Interagency HIV Study (WIHS), the largest ongoing
longitudinal study of HIV disease in women in the United States.
The WIHS is a multi-center study of HIV seropositive and HIV
seronegative women established in 1994. The HIV+ and HIV2
cohorts were recruited from similar sources and were matched on
demographics and key risk factors, such as age, race/ethnicity,
education, injection drug use, and number of sexual partners, as
described in Barkan et al. [35] and Bacon et al. [36]. The WIHS
protocol includes a baseline visit and follow-up visits on a
semiannual basis, which include a physical examination, collection
of blood for biomarker measurement, and completion of various
questionnaires and tasks. Participants were recruited for this sub-
study during their semiannual WIHS visits at the CORE Center at
Cook County Health and Hospital Systems, by prior review of
WIHS variables to pre-identify women for each group, who were
then approached and the ones who consented were enrolled
sequentially into the current sub-study. HIV serostatus was verified
by repeatedly reactive enzyme-linked immunosorbent assay
(ELISA) and confirmed by Western Blot. Women whose primary
first language was not English, who had a history of closed head
injury with loss of consciousness exceeding 30 minutes, open head
injury, psychotic disorders, or current neuroleptic use were
excluded from participation.
The majority of the participants (81%) were African-American,
14% were Hispanic, and 5% were white. Thirty-one of the women
were HIV-seropositive (HIV+) and 26 were HIV-seronegative
(HIV2). Further, 28 of the women had a history of crack cocaine
and/or heroin use (DU+) and 29 had no such history (DU2).
Overall, 14 participants were HIV+/DU+, 17 were HIV+/DU2,
14 were HIV2/DU+, and 12 were HIV2/DU2 (see Tables 1
and 2).
Assessment procedures
Intellectual Functioning. Intellectual functioning was esti-
mated with the Wechsler Test of Adult Reading (WTARTM) [37].
Substance Use. Substance use was quantified by the Kreek-
McHugh-Schluger-Kellogg Scale (KMSK) [38], a brief screening
instrument which indexes the degree of self-exposure to four
different classes of drugs (alcohol, tobacco, cocaine, and heroin)
defined as the frequency, amount, and duration of use during the
Computational Modeling in HIV and Drug Use
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lifetime period of greatest consumption of these substances. The
total score for each of the four classes of substances on the KMSK
was determined by summing the frequency, duration, and amount
of use of each substance. The KMSK shows excellent associations
with DSM-IV criteria for substance dependence as measured by
the SCID, with very high specificity and sensitivity for opiates
(100% and 99% respectively) and cocaine (97% and 94%
respectively) [38]. Scores range from 0–12 for tobacco, 0 to 13
for alcohol and for opiates, and from 0 to 16 for cocaine. As
recommended by Tang et al. [39] who evaluated the KMSK with
poor urban predominantly female African-Americans, a popula-
tion very similar in demographic characteristics to our partici-
pants, subjects were considered as DU+ if they scored a minimum
of 6 on the cocaine subscale and/or 2 on the opiates subscale. The
range of scores on the cocaine scale of HIV+/DU+ participants
who reported cocaine use was between 10 and 16, and between 6
and 16 in HIV2/DU+ participants reporting cocaine use. On the
opiates scale, scores of HIV+/DU+ participants who reported
opiate use ranged between 6 and 11 and scores of HIV2/DU+
participants reporting opiate use ranged between 7 and 13 (see
also Table 2). Given that the KMSK scale does not assess
marijuana use, we did not have a formal measure of severity of
Table 1. Demographic and HIV disease characteristics of participants.
HIV+/DU+ (n = 14) HIV+/DU2 (n = 17) HIV2/DU+ (n =14) HIV2/DU2 (n =12) p
Age (SD) 43.3 (4.9) 38.8 (8.3) 40.6 (7.1) 33.5(8.5) p= .01
Education (SD) 11.3 (1.01) 10.9 (2.1) 11.5 (.73) 11.7 (.49) p= .51
Race (%) p= .43
African-American 86 71 93 75
Hispanic 7 23 0 25
Caucasian 7 6 7 0
WTAR Reading 27.3 (5.1) 29.8 (11.4) 25.2 (10.1) 28.6 (10.6) p= .59
cART p= .90
Currently on cART (%) 86 88 - -
Not on cART (%) 14 12 - -
CD4 count at closest WIHS visit 428.07 (273.9) 481.6 (245.6) - - p= .57
Nadir CD4 count 324.4 (174.1) 288.1 (85.9) - - p= .47
Note: Unless otherwise stated, data are presented as means and standard deviations.
doi:10.1371/journal.pone.0068962.t001
Table 2. Substance use characteristics of participants.
HIV+/DU+
(n = 14)
HIV+/DU2
(n =17)
HIV2/DU+
(n = 14)
HIV2/DU2
(n =12) p
KMSK Total Scores
Alcohol 8.43 6.59 7.79 8.0 p= .56
Tobacco 10.21 2.53 9.64 5.17 p,.0001
Cocaine 13.43 .12 10.07 0 p,.0001
Heroin 3.07 0 5.21 0 p,.0001
KMSK lifetime heroin use
Never used (%) 9 (64) 17 (100) 6 (43) 12 (100)
20–100 times/lifetime (%) 1 (7) 0 1 (7) 0
.100 times/lifetime (%) 4 (29) 0 7 (50) 0
KMSK lifetime cocaine use
Never used (%) 1 (7) 16 (94) 3 (22) 12 (100)
Fewer than 20 times/lifetime (%) 0 1 (6) 1 (7) 0
20–100 times/lifetime (%) 0 0 1 (7) 0
.100 times/lifetime (%) 13 (93) 0 9 (64) 0
KMSK Current Use
Cocaine (%) 1 (7) 0 2 (14) 0
Heroin (%) 0 0 2 (14) 0
Marijuana Use
Proportion of WIHS visits reporting marijuana use .13 (.23) .24 (.38) .28 (.34) .35 (.39) p= .42
doi:10.1371/journal.pone.0068962.t002
Computational Modeling in HIV and Drug Use
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marijuana use. However, we had available information on
proportion of WIHS visits at which subjects reported marijuana
use within the previous 6 months, which we used as an index of
marijuana use (Table 2).
HIV Risk Behaviors and Adherence to HIV Medication
Schedule. We administered the Risk Assessment Battery (RAB),
to measure HIV risk behaviors during the past 6 months [40]. It is
comprised of two subscales: ‘‘Needle Use’’ (RAB-NU) and ‘‘Sexual
Practices’’ (RAB-SP) reflecting frequency or quantity of specific
behaviors that a participant may have engaged in during the past 6
months. Most participants in our sample were not actively using
injection drugs during the 6 months prior to their assessment;
therefore, the variability of scores on the RAB-NU subscale was
extremely restricted, median= 0, IQR [0, 0]. For the RAB-SP
subscale, our sample displayed ample variability (range= [0, 13],
median = 4, IQR [2,5]). Given that essentially all of the variance in
the RAB total scores was the result of responses on the RAB-SP
subscale, we only used the RAB-SP in the statistical analyses.
Degree of adherence to antiretroviral therapy among HIV+
participants was evaluated by asking participants at their nearest
WIHS core visit how closely they have followed their HIV
medication schedule during the past six months. Responses were
coded as follows: 1 = never; 2 = some of the time; 3 = about K of
the time; 4 =most of the time; 5 = all of the time.
Decision-Making. Participants were administered a com-
puterized version of the Iowa Gambling Task (IGT) [7]. The task
requires participants to make selections from four decks of cards
(A, B, C, and D) with the goal of maximizing profit on a loan of
play money. Participants are instructed to select one card on each
trial and are told that each card selection would be associated with
a win of some money; however, occasionally, a particular card
selection would also result in a loss. Decks A and B are
‘‘disadvantageous’’ in that they are associated with high immediate
rewards but even higher subsequent losses and therefore are more
costly in the long run. Decks C and D, on the other hand, are
considered ‘‘advantageous’’ because they result in an overall long-
term gain. Ultimately, selecting from the ‘‘good decks’’ results in a
net profit at the end of the task, whereas selecting from the ‘‘bad
decks’’ results in a net loss. Importantly, participants are not told
that the different decks are associated with differential schedules of
rewards and punishments and they have to learn the task
contingencies by trial-and-error as the task progresses. Participants
are given visual and auditory feedback about their gains and losses
after each card selection. Normal healthy adults typically learn
which decks are advantageous for maximizing monetary gain, as
indicated by their increasing proportion of choices from the
advantageous decks.
The task consists of 100 trials. Each deck of cards has 60 cards
and if the cards ran out from a deck, subjects had to choose from
other decks thereafter. If one of the decks was depleted during the
task (i.e., chosen 60 times), the remaining trials were not used for
the computational modeling analysis because the structure of the
task at that point becomes a choice among 3 decks instead of 4
decks. Unlike the original IGT [11], the amount of gains are not
fixed to $100 or $50, but decks pay an average of $100 and $50. In
addition, the amounts of payoffs in all four decks increase across
each block of ten cards. See Bechara et al. [7] for more details on
the modifications.
Computational Modeling Analysis of IGT
To determine which computational model best fit our data, we
compared three models: (1) the ‘‘classic’’ Expectancy Valence
Learning (EVL) model [22]; (2) the Prospect Valence Learning
(PVL) model [41] with the delta learning rule [42]; and (3) the
PVL model with the decay-reinforcement learning rule [43]. The
PVL model with the decay-reinforcement learning rule had the
best model-fits (see Appendix S1 in File S1 for details of the model
comparisons).
The outcome evaluation in the PVL model follows the prospect
utility function which has diminishing sensitivity to increases in
magnitude and differential sensitivity to losses versus gains. The
PVL model has four parameters (see Appendix S2 in File S1 for
mathematical details of the model): (1) the shape of the utility function
parameter a (0,a,1), which reflects reward sensitivity. As this
parameter approaches 1 (i.e., high reward sensitivity), the
subjective utilities of outcomes increase in direct proportion to
the actual outcomes, but as the parameter approaches 0 (i.e., low
reward sensitivity), the subjective utilities increase non-linearly in a
step-wise fashion, such that all gains and all losses are subjectively
equal; (2) the loss aversion parameter l, (0,l,5), which
determines the sensitivity to losses compared to gains and reflects
the tendency to select the alternative that decreases the probability
of losses even if it is associated with lower expected gains (Ahn et
al. 2008). A value of loss aversion (l) greater than 1 indicates that
the individual is more sensitive to losses than to gains. Conversely,
a value of l less than 1 indicates that the individual is more
sensitive to gains than to losses; (3) the recency parameter A
(0,A,1), which determines how much the past expectancy is
discounted. A high value of A indicates good learning/less memory
decay, whereas a low value of A indicates rapid memory decay; (4)
the consistency parameter (c), which indicates how close the
decision-maker’s selections adhere to their expectancies of the
decks’ utilities. Consistency (c) values range between 0 and 5,
which allows for totally random and presumably impulsive choices
(c=0) to almost deterministic choices (c=5). The softmax choice
rule [44] was used to compute the probability of choosing each
deck.
In sum, the PVL model has four free parameters that reflect
distinct psychological processes: (1) a, utility shape (reward
sensitivity); (2) l, loss aversion; (3) A, recency (learning/memory);
and (4) c, choice consistency. We used hierarchical Bayesian
analysis (HBA) for estimating model parameters (see Appendix S3
in File S1 for details). HBA has several advantages over null
hypothesis significance testing (NHST) and provides more robust
and stable estimation of individual and group differences (see [45]
for review). We evaluated group differences on model parameters
estimated from hierarchical Bayesian analysis by examining 95%
highest density interval (HDI), which is an interval that spans 95%
of the posterior distribution [46]. For example, if 95% HDI of
group differences excludes zero, this would indicate that the
groups are credibly different. For clarity, we also report in parallel
NHST results.
Results
Demographic, Substance Use, and HIV Disease
Characteristics of Participants
Group differences in continuous variables were examined using
one way ANOVAs with Tukey HSD post hoc comparisons where
appropriate. Categorical variables were examined using Pearson’s
chi square analyses. Groups were well matched on education,
ethnicity, and estimated premorbid intelligence (Table 1). There
were significant group differences in age (F(3,53) = 4.05, p= .01),
with the HIV+/DU+ group being older than the HIV2/DU2
group. Among HIV+ participants, there were no group differences
between the DU+ and DU2 groups on current CD4 count
(F(1,29) = .33, p= .57), nadir CD4 (F(1,29) = .54, p= .47), or how
closely they followed their recommended HIV medication dosing
Computational Modeling in HIV and Drug Use
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schedule (x2(3) = 2.7, p= .44). Eighty-six percent of HIV+/DU+
participants were currently on cART, and 14% were not on any
antiretroviral therapy. Among HIV+/DU2 participants, 88%
were currently on cART and 12% were not taking any HIV
medication. The two DU+ groups were also well matched on
substance use characteristics as measured by the KMSK (Table 2).
Specifically, there were no significant group differences in total
cocaine scores (F(1,26) = 2 .73, p= .11), heroin scores (F(1,26) = 1.48,
p= .24), tobacco scores (F(1,26) = 0.31, p= .59) and alcohol scores
(F(1,26) = 0.19, p= .67) between HIV+/DU+ and HIV2/DU+
participants. The two DU+ groups scored significantly higher than
the two DU2 groups in total cocaine scores (F(3,53) = 45 .78,
p,.0001), heroin scores (F(3,53) = 8.65, p,.0001) and tobacco
scores (F(3,53) = 18.59, p,.001), but not in alcohol scores
(F(3,53) = .70, p= .56).
Behavioral Performance on the Iowa Gambling Task
IGT performance was analyzed with a mixed model ANOVA
with trial block (Blocks 1–5) as the within subject factor, and HIV
(HIV+, HIV2) and drug use (DU+, DU2) as the between-
subjects factors. When sphericity could not be assumed, Green-
house-Geisser correction was applied. The analysis revealed no
significant main effects or interactions (all p’s..1). In general, all
four groups made more disadvantageous than advantageous
selections throughout the task, as indicated by their predominantly
negative net scores (HIV+/DU+: 21.14 (5.8); HIV+/DU2: 24.4
(6.5); HIV2/DU+: 25.9 (6.8); HIV2/DU2: .17 (5.2). Further,
none of the groups learned to switch their selections from the
disadvantageous to the advantageous decks as the task progressed,
indicated by the lack of significant main effect of trial block
(F(4,212) = 1.11, p= .35). There were also no group differences in
preferences for specific decks throughout the task, with partici-
pants across all four groups making more choices from deck B than
from any of the other decks (F(2.29,121.1) = 17.26, p,.001, with
Greenhouse-Geisser correction for violation of sphericity applied).
Eighteen percent of participants’ choices were from Deck A, 34%
of choices - from Deck B, 23% - from Deck C, and 25% - from
Deck D (Figure 1).
Computational Modeling Results
We next compared the four groups on the parameter estimates
from the PVL model. Table 3 summarizes PVL model parameter
estimates from the HBA. We examined whether HIV or DU affect
model parameters by comparing the control group (HIV2/DU2)
with the groups with single risk factor (HIV+/DU2 and HIV2/
DU+) (i.e. ‘‘main effects’’ of HIV or DU). Among the four
parameters, we found that DU was associated with the learning/
memory parameter A (Figure 2) and loss aversion _ (Figure 3),
while HIV was related only on loss aversion (Figure 3). HIV2/
DU+ participants had compromised learning/memory function
indicated by a reduced recency parameter (Figure 2) and lower loss
aversion than HIV2/DU2 control participants (mean differ-
ence = .44, 95% HDI of group differences from .18 and .70;
NHST: t(24) = 8.86, p,.0001, see also Figure 3). On the other
hand, HIV+DU2 participants were less averse to loss compared
to HIV2/DU2 participants (mean difference = 1.59, 95% HDI
of group differences from .33 and 2.93; NHST: t(27) = 8.54,
p,.0001).
Given the significant group differences in age, we conducted
additional Bayesian and NHST analyses controlling for age, which
revealed essentially identical findings. See Appendix S3 in File S1
for details of the Bayesian analysis controlling for age.
Associations of Modeling Parameters with HIV Risk
Behaviors and HIV Medication Adherence
Bivariate correlational analyses, conducted separately for each
of the four groups explored associations between the four
computational modeling parameters on the IGT and HIV risky
sexual behaviors as measured by the RAB-SP. Significant
associations with RAB-SP were observed only in the HIV+/
DU+ group, where it was related to reward sensitivity (r = .59,
p= .02) and learning/memory (r = .58, p= .03). No significant
correlations between modeling parameters and the RAB-SP were
observed in the other groups.
Additional correlational analyses restricted to the two HIV+
groups explored the associations between modeling parameters
and how closely participants followed their recommended HIV
medication schedule. Again, a significant correlation was observed
only within the HIV+/DU+ group between consistency (c) and
degree of medication adherence (rs= .71, p,.01), whereas no
significant associations were noted in the HIV+/DU2 group.
Discussion
To our knowledge, this is the first study that employs
computational modeling to investigate the effects of HIV and
history of drug use on decision-making. Results from these
analyses indicate that even within the context of no differences in
overt behavioral performance, there are notable differences in the
underlying components of decision-making that appear to be
differentially related to HIV and drug use. Specifically, we found
that whereas both HIV and DU were associated with lower loss
aversion, DU was additionally related to compromised learning/
memory. Importantly, results revealed that some of the cognitive
and motivational processes involved in decision-making may have
functional significance for HIV infected women with a history of
illicit drug use (HIV+/DU+), among which some of the
parameters were related to risky sexual behaviors and reduced
adherence to HIV medication dosing schedules.
Figure 1. IGT performance (overall proportion of choices from
each deck). Error bars indicate ±1 SEM.
doi:10.1371/journal.pone.0068962.g001
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Although deficits in decision-making are a common finding
in the addiction literature [7,8], the underlying nature of these
deficits has only recently begun to be investigated. The
current state of our knowledge about decision-making
processes in substance dependent HIV infected women is
limited. The use of computational models of decision-making
allowed us to conduct an in-depth investigation of such
processes in women and to demonstrate that both HIV and
DU are associated with decision-making biases related to
relative insensitivity to losses. Given that to our knowledge, no
studies have applied the computational modeling approach to
HIV, the association of HIV with loss aversion that we
observed needs to be replicated and explored in larger and
mixed gender studies. On the other hand, our findings on the
association of DU with loss aversion is consistent with the
literature, which reveals reduced loss aversion among users of
different classes of drugs such as cocaine [20], cannabis [24]
or alcohol [25] relative to controls.
Computational modeling analyses further revealed that a
history of cocaine and/or heroin use was specifically associated
with the learning/memory parameter of the IGT, whereas HIV
was not significantly related to this component of decision-making.
Learning and memory processes play a major role in the IGT, as
good performance on the task requires participants to learn by
trial-and-error which decks are advantageous and to proceed to
select consistently from these decks in order to achieve optimal
performance. Learning and memory processes are also centrally
involved in drug addiction and are of particular etiological
significance for the chronic-relapsing nature of the disease [47–
50]. The effects of DU on learning/memory that we found are in
line with previous studies with drug users [23–25], although such
effects are not invariably observed (see [20]) and need to be
investigated further. Of particular relevance to the current study,
Stout and colleagues [23] found that in women, only the learning/
memory parameter distinguishes between drug using and control
participants, whereas the motivational parameter discriminated
between drug using men and controls. Similar sex differences have
also been noted in other aspects of the IGT. In terms of behavioral
performance, research consistently demonstrates that men typi-
cally show better performance on the IGT than women
[20,33,34,51–55]. There is also evidence that drug-using men
perform significantly worse than healthy control men on the task,
whereas drug-using women perform significantly better than
healthy women [23]. Our study provides the first in depth
investigation of the psychological processes involved in complex
decision-making in women with HIV and DU. Given that no
studies to date have directly compared male and female HIV+
drug users both in terms of overall performance and on
component processes of decision-making, future studies should
systematically investigate whether the associations that we
observed are gender specific.
Contrary to predictions, we found no significant group
differences in behavioral performance on the IGT, although
performance of all four groups remained overall in the impaired
range. This finding stands in contrast to numerous studies
reporting that drug users are behaviorally more impaired than
controls [7,8] and the growing literature revealing similar
impairments in HIV [5,6,18]. However, it should be noted that
drug users are not invariably impaired on the IGT, as evidenced
by studies reporting no group differences between drug users and
controls [56,57]. The lack of group differences in task performance
in our study could be related to the distinct nature of our HIV2
Table 3. Means and (standard deviations) of computational
modeling parameters.
HIV+DU+ HIV+DU2 HIV2DU+ HIV2DU2
Recency (A) .20 (.04) .50 (.19) .21 (.06) .64 (.18)
Reward Sensitivity
(a)
.38 (.04) .26 (.02) .36 (.03) .18 (.02)
Consistency (c) .49 (.40) .55 (.38) .62 (.38) .36 (.30)
Loss Aversion (l) .06 (.01) .25 (.16) .07 (.01) 1.84 (.75)
doi:10.1371/journal.pone.0068962.t003
Figure 2. Parameter estimates of A (learning/memory). Note: 300 random samples were drawn from the posterior distributions for each
group. Dashed lines indicate mean values for each group. HDI =mean and 95% HDI range.
doi:10.1371/journal.pone.0068962.g002
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and DU2 control participants, who were recruited and selected
from the same high risk population as the HIV+ participants,
which is indeed one of the unique aspects of the WIHS parent
study. Another somewhat unexpected finding was the absence of
learning effects in the performance of all four groups on the IGT.
Even though this finding was surprising, it is in line with studies
showing that the typical learning effects on the IGT are displayed
more commonly by men than by women [51]. The observed
inconsistencies in the literature could be due to additional
differences in sample characteristics such as age, type of drug(s)
used, or length of abstinence. For instance, most of the participants
in our study were generally older than participants in previous
studies (e.g. [23–25]). Further, whereas most previous computa-
tional modeling studies have assessed the effects of drug use with
current users [9,20,23,24], only about 10% of our DU+
participants were current drug users. In relation to our findings,
this suggests that the overt behavioral manifestations of impair-
ments in decision-making may dissipate with abstinence from drug
use; however the underlying decision-making biases may remain
and may continue to influence important daily activities and risk
behaviors. Of note, the learning/memory effect that we observed
appears to have a real-world functional significance for the women
with co-occurring HIV and history of drug use (HIV+/DU+), as
suggested by its relationship with high risk sexual activities on the
RAB-SP, which were also associated with increased reward
sensitivity in this group. Yet, the association between learning/
memory and sexual risk taking was somewhat counterintuitive, in
that better learning/memory was associated with higher rates of
risky sexual behaviors in HIV+/DU+ participants. While these
findings need to be explored further, they raise interesting
questions regarding decision-making biases and correlates of risky
sexual behaviors in HIV+/DU+ women. Further, although high-
risk behaviors in drug users have been a subject of intense
investigation, most studies have investigated HIV seronegative
drug users, whereas the mechanisms driving risky sexual behaviors
in HIV seropositive individuals still remain poorly understood.
Our results also revealed that a different component of decision-
making, namely consistency of responding (c) is positively
associated with a different type of functional outcome, i.e. degree
of adherence to HIV medication schedule. This indicates that an
erratic choice pattern or decision-making style may have
important negative implications for daily functional behaviors
such as medication management, that are critical for suppressing
HIV viral replication and disease progression.
This study has several limitations. We did not conduct formal
diagnostic interviews for substance use disorders, yet the high
correlations between KMSK scores and DSM-IV criteria for
substance dependence measured by the SCID increase our
confidence in the classification of participants into DU+ and
DU2 groups. Given that we did not conduct urine toxicology
screens, it is possible that not all participants were drug-free at the
time of testing. Other caveats are our relatively small sample size
and the somewhat non-representative nature of the WIHS cohort,
which may limit the generalizability of our findings. Specifically,
participants enrolled in the WIHS are consistently offered or
referred for services such as HIV counseling, targeted health
assessments, health education, treatment for substance abuse,
mood disorders, and HIV primary and specialty care [35] that
may not be as readily available in the context of standard care.
Also worth acknowledging is that the combinations of antiretro-
viral medications (cART) used by 87% of our HIV+ participants
may have affected their neurocognitive functioning. Different
cART medications are characterized by varying degrees of CNS
penetration effectiveness, which may differentially affect neuro-
cognitive function. The CNS Penetration Effectiveness (CPE)
Scale introduced by Letendre and colleagues [58] provides a
quantitative index of the relative capacity for an antiretroviral
drug to cross the blood brain barrier. However, the relationship
between CNS penetration effectiveness of antiretroviral (cART)
cocktails and neurocognitive performance is not straightforward,
Figure 3. Parameter estimates of l (loss aversion). Note: 300 random samples were drawn from the posterior distributions for each group.
Dashed lines indicate mean values for each group. HDI =mean and 95% HDI range.
doi:10.1371/journal.pone.0068962.g003
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with some studies reporting positive relationships between CPE
scores and neurocognitive performance [59–61], whereas others
report inverse [62,63] or no relationships [64]. In terms of
computational modeling, it should be noted that the validity of the
conclusions must be understood within the limits of the fit of the
computational models. We used the PVL model with the decay-
reinforcement learning rule because it showed the best model-fit
and because previous simulation studies show relatively accurate
parameter values and better parameter consistency across tasks
than other competing models. However, the model’s performance
on long-term predictions appears worse than other model such as
the PVL model with the delta rule. Future studies should focus on
developing models that have both good short-term and long-term
prediction accuracy. Finally, study findings are limited to the IGT,
which was our only measure of decision-making; therefore, these
findings need to be examined further with other decision-making
tasks.
In summary, this study extends findings with drug users to a
new and relatively understudied population of middle-aged
women with a history of crack cocaine and/or heroin use and is
the first to apply a formal mathematical model to examine the
effects of HIV on cognitive, motivational, and affective processes
involved in complex decision-making. Our findings underscore the
potential importance of using performance indices such as
computational modeling parameters, which may be more sensitive
for revealing the underlying cognitive and motivational decision-
making biases in different clinical populations than standard
indices of overt behavioral performance. The current study
contributes to a growing line of literature which shows that
different psychological processes may underlie similar overt
behavioral performance in various clinical groups and may be
associated with different functional outcomes.
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